natgillin/translations-raw huggingface dataset:
Talk to your doctor before using Besremi: - if you have thyroid disease. 
Razgovarajte sa svojim liječnikom prije nego počnete primjenjivati Besremi: - ako imate bolest štitnjače.
The effect of Besremi during pregnancy is not known. 
Učinak lijeka Besremi tijekom trudnoće nije poznat.
Before use, the pre-filled pen should be brought to room temperature (15 °C - 25 °C) for up to 15 minutes. 
Prije uporabe napunjenu brizgalicu treba pustiti da tijekom 15 minuta postigne sobnu temperaturu (15°C - 25°C).
As ropeginterferon alfa-2b may have the same effect, this medicinal product is not recommended during pregnancy. 
S obzirom da ropeginterferon alfa-2b može imati isti učinak, ovaj lijek se ne preporučuje tijekom trudnoće.
• If you are unable to reach the required dose setting by turning the dose knob, your pen may not have sufficient medicine left. 
• Ako ne možete dosegnuti potrebnu dozu okretanjem kotačića za odabir doze, u Vašoj brizgalici možda nije ostalo dovoljno lijeka.
• Hold the pen so that the display window and the label are visible during the injection. 
• Držite brizgalicu tako da su prozorčić za prikaz doze i naljepnica vidljivi tijekom primjene injekcije.
The maximum recommended single dose is 500 micrograms injected every two weeks. 
Maksimalna preporučena pojedinačna doza je 500 mikrograma injicirati svaka 2 tjedna.
If you have health problems which may lead to eye problems such as diabetes or high blood pressure, you doctor should check your vision also during treatment. 
Ako imate problema sa zdravljem koji mogu uzrokovati probleme s očima, poput šećerne bolesti ili visokog krvnog tlaka, Vaš liječnik treba provjeravati Vaš vid i tijekom liječenja.
You should brush your teeth thoroughly twice daily and have regular dental checks. 
Morate četkati zube temeljito dva puta na dan te redovito odlaziti na stomatološke preglede.
However, if more than 2 days have passed since you missed the dose, leave out the dose and inject the next dose when it is due. 
Međutim, ako je prošlo više od 2 dana od propuštene doze, preskočite tu dozu i injicirajte sljedeću dozu kada za nju dođe vrijeme, prema uobičajenom rasporedu.
- periodontal (affecting gums) and dental disorders, change in colour of the tongue 
- parodontalni (koji zahvaćaju desni) i dentalni poremećaji, promjena boje jezika
- if you have diabetes or high blood pressure − your doctor may ask you to have an eye examination. 
- ako imate šećernu bolest ili visoki krvni tlak − Vaš liječnik Vas može poslati na pregled očiju.
Responder % (n/N) 
Ispitanici s odgovorom % (n/N)
Dose titration phase 
Doziranje Faza titracije
If you stop using Besremi 
Ako prestanete primjenjivati Besremi
What Besremi looks like and contents of the pack 
Kako Besremi izgleda i sadržaj pakiranja
• Hold the push button down and wait for at least 10 seconds before removing the needle. 
• Držite gumb pritisnutim nadolje i pričekajte barem 10 sekundi prije vađenja igle.
3F, No. 28, Keya West Road 
28, Keya West Road Daya District
Name and address of the manufacturer(s) responsible for batch release AOP Orphan Pharmaceuticals AG 
Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet AOP Orphan Pharmaceuticals AG
Your doctor or pharmacist will explain to you how to use the two pens. 
Vaš liječnik ili ljekarnik će Vam objasniti kako primijeniti dvije brizgalice.
Polycythaemia vera is a type of cancer in which the bone marrow produces too many red blood cells, white blood cells and platelets (cells that help the blood to clot). 
Policitemija vera je vrsta raka krvi u kojem koštana srža proizvodi previše crvenih krvnih stanica, bijelih krvnih stanica i trombocita (stanica koje pomažu zgrušavanju krvi).
Patients should brush their teeth thoroughly twice daily and have regular dental examinations. 
Bolesnici moraju četkati zube temeljito dva puta na dan te redovito odlaziti na stomatološke preglede.
Binding to IFNAR initiates a downstream signalling cascade through the activation of kinases, in particular Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) and activator of transcription (STAT) proteins. 
Vezivanje na IFNAR pokreće silaznu signalnu kaskadu kroz aktivaciju kinaza, posebice Janus kinaze 1 (JAK1) i tirozin kinaze 2 (TYK2) te aktivator transkripcije proteina (engl. signal transducer and activator of transcription, STAT).
The push button should be pressed in completely and held down for at least 10 seconds before removing the needle. 
Potisni gumb treba pritisnuti do kraja i držati tako pritisnutim barem 10 sekundi prije izvlačenja igle.
not known pulmonary fibrosis#, pneumonia#, pulmonary arterial hypertension#* 
nepoznato plućna fibroza#, pneumonija#, plućna arterijska hipertenzija#*
Contents of the pack and other information What Besremi contains 
Sadržaj pakiranja i druge informacije Što Besremi sadrži
- if you have or had severe mental disorders (such as depression or suicidal thoughts or if you tried to kill yourself). 
- ako imate ili ste imali teži psihički poremećaj (poput depresije ili misli o samoubojstvu ili ako ste se pokušali ubiti).
AOP Orphan Pharmaceuticals AG Wilhelminenstrasse 91/II f 1160 Vienna 
AOP Orphan Pharmaceuticals AG Wilhelminenstrasse 91/II f 1160 Beč
Then press the push button until the display window shows “0”. 
Potom pritisnite potisni gumb dok prozorčić ne prikaže „0“.
Apply an adhesive plaster if needed. 
Prema potrebi primijenite flaster.
- if you have or had an autoimmune disease (such as rheumatoid arthritis, psoriasis or inflammatory bowel disease). 
- ako imate ili ste imali autoimunu bolest (poput reumatoidnog artritisa, psorijaze ili upalne bolesti crijeva).
The most common adverse reactions are leukopenia (19.1%), thrombocytopenia (18.5%), arthralgia (12.9%), fatigue (12.4%), increased gamma-glutamyltransferase (11.2%), influenza like illness (10.7%), myalgia (10.7%), pyrexia (8.4%), pruritus (8.4%), increased alanine aminotransferase (8.4%), anaemia (7.9%), pain in extremity (6.7%), alopecia (6.7%), neutropenia (6.7%), increased aspartate aminotransferase (6.2%), headache (6.2%), diarrhoea (5.6%), chills (5.1%), dizziness (5.1%) and injection site reaction (5.1%). 
Najčešće nuspojave su leukopenija (19,1%), trombocitopenija (18,5%), artralgija (12,9%), umor (12,4%), povećana razina gama-glutamiltransferaze (11,2%), bolest nalik influenci (10,7%), mijalgija (10,7%), pireksija (8,4%), pruritus (8,4%), povišena razina alanin aminotrasnferaze (8,4%), anemija (7,9%), bol u ekstremitetima (6,7%), alopecija (6,7%), neutropenija (6,7%), povišena razina aspartat aminotransferaze (6,2%), glavobolja (6,2%), proljev (5,6%), neutropenija (5,1%), zimica (5,1%), omaglica (5,1%) te reakcija na mjestu primjene injekcije (5,1%).
Interferon alfa therapy has been associated with hepatotoxicity characterized by potentially significant increases in liver enzymes. 
Terapija interferonom alfa povezana je s hepatotoksičnošću koja je karakterizirana potencijalno značajnim porastima razina jetrenih enzima.
Obese or underweighted patients 
Pretili ili pothranjeni bolesnici
Serious adverse reactions are depression (1.1%), atrial fibrillation (1.1%) and acute stress disorder 
Ozbiljne nuspojave su depresija (1,1%), fibrilacija atrija (1,1%) te akutni stresni poremećaj (0,6%).
Cardiovascular system 
Kardiovaskularni sustav
- if you have or had severe heart problems (such as heart attack or stroke). 
- ako imate ili ste imali teške probleme sa srcem (poput srčanog udara ili moždanog udara).
The dose is titrated individually with a recommended starting dose of 100 micrograms (or 50 micrograms in patients under another cytoreductive therapy). 
Doza se titrira individualno za svakog bolesnika s preporučenom početnom dozom od 100 mikrograma (ili 50 mikrograma u bolesnika koji su podvrgnuti drugoj citoreduktivnoj terapiji).
If you are a woman of childbearing potential, your doctor will discuss with you if effective birth control should be used during your treatment with Besremi. 
Ako ste žena u reproduktivnoj dobi, Vaš liječnik će raspraviti s Vama trebate li primjenjivati učinkovitu metodu kontracepcije tijekom liječenja lijekom Besremi.
Phlebotomy as rescue treatment to normalise blood hyperviscosity may be necessary. 
Može biti potrebna felbotomija kao metoda „rescue“ liječenja kako bi se postigla normalizaciju hiperviskoznosti krvi.
If you forget to use Besremi 
Ako ste zaboravili primijeniti Besremi
The most common adverse reactions (including number of patients, incidence rate, severity grade, necessity for dose adaptation and outcome) reported during the ropeginterferon alfa-2b clinical development program are summarised in Table 1. 
Najčešće nuspojave (uključujući broj bolesnika, stopu incidencije, stupanj težine, potrebu za prilagodbom doze i ishod) prijavljene tijekom programa kliničkog razvoja ropeginterferona alfa-2b sažete su u Tablici 1.
The European Medicines Agency has waived the obligation to submit the results of studies with Besremi in all subsets of the paediatric population in the treatment of polycythaemia vera (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Besremi u svim podskupinama pedijatrijske populacije za liječenje policitemije vere (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
*Class label for interferon medicinal products, see below pulmonary arterial hypertension. 
*Oznaka za klasu lijekova koji sadrže interferon, vidjeti u nastavku plućnu arterijsku hipertenziju.
In addition, dry mouth could damage teeth and the lining of the mouth during long-term treatment with Besremi. 
Osim toga, suha usta mogu oštetiti zube i sluznicu usta tijekom dugotrajnog liječenja lijekom Besremi.
A new, sterile needle as provided with the pre-filled pen must be carefully attached onto the pre-filled pen before each injection. 
Novu sterilnu iglu, koja dolazi priložena uz napunjenu brizgalicu, mora se pažljivo pričvrstiti na napunjenu brizgalicu prije svake primjene injekcije.
These actions may be involved in the therapeutic effects of interferon alfa in polycythaemia vera. 
Ta djelovanja mogu biti uključena u terapijske učinke interferona alfa kod policitemije vere.
Pharmacokinetics were not evaluated in patients with increased severity of hepatic impairment. 
Farmakokinetika nije procijenjena u bolesnika s težim oštećenjem jetre.
Patients who experience dizziness, somnolence or hallucination (see section 4.8) during Besremi therapy should avoid driving or using machines. 
Bolesnici u kojih se javi omaglica, somnolencija ili halucinacije (vidjeti dio 4.8), tijekom terapije lijekom Besremi, moraju izbjegavati upravljanje vozilima ili rad sa strojevima.
The selected dose must align with the dot and dose display window. 
Odabrana doza mora se poravnati s točkom na prozorčiću za prikaz doze.
If an increase of haematological parameters (haematocrit, platelets, leukocytes) is observed, the dose and/or dosing interval needs to be adapted individually. 
Ako se uoči porast u hematološkim parametrima (hematokrit, trombociti, leukociti), dozu i/ili interval doziranja treba prilagoditi pojedinačnom bolesniku.
Based on data in monkeys, it is approx. 80%, similar to that seen for pegylated interferon alfa-2a. 
Na temelju ispitivanja na majmunima, iznosi približno 80%, slično onom uočenom za pegilirani alfa-2a.
This droplet is normal and does not mean that you underdosed. 
Ta je kapljica normalna i ne znači da ste primili nedovoljnu dozu lijeka.
Patients were stratified by previous exposure to hydroxycarbamide, age at screening (≤60 or >60 years) and presence of thromboembolic events in the past. 
Bolesnici su bili stratificirani prema prethodnoj izloženosti hidroksikarbamidu, dobi prilikom probira (≤60 ili >60 godina), te anamnezi tromboembolijskog događaja.
Insert the needle at a 90 degrees angle until the blue protective sleeve on the needle is no longer visible. 
Umetnite iglu pod pravim kutom, dok plava zaštitna navlaka na igli ne bude više vidljiva.
This medicinal product is contraindicated in patients with severe preexisting cardiovascular disease or patients who had recently suffered from a stroke or myocardial infarction (see section 4.3). 
Ovaj lijek je kontraindiciran u bolesnika s teškom postojećom kardiovaskularnom bolesti ili bolesnika koji su nedavno pretrpjeli moždani udar ili infarkt miokarda (vidjeti dio 4.3).
The use of Besremi is not recommended during pregnancy. 
Primjena lijeka Besremi ne preporučuje se tijekom trudnoće.
Then, tap the pen (cartridge holder) gently with your fingers to allow any air bubbles to rise to the top of the cartridge holder. 
Potom blago lupkajte brizgalicu (nosač uloška) prstima kako biste omogućili da se svi mjehurići zraka podignu u vrh nosača uloška.
Ropeginterferon alfa-2b may inhibit the activity of CYP1A2 and CYP2D6 and thus may increase the blood concentrations of these medicinal products. 
Ropeginterferon alfa-2b može inhibirati aktivnost CYP1A2 i CYP2D6 i tako povećati koncentracije tih lijekova u krvi.
Besremi contains benzyl alcohol. 
Besremi sadrži benzilni alkohol.
The recommended injection site is the abdominal skin around but not within 5 cm of the navel or the thigh. 
Preporučeno mjesto davanja injekcije je koža u području abdomena oko, ali ne unutar, 5 cm od pupka ili koža bedra.
Abbreviations: CTCAE, common terminology criteria for adverse events; n.r., not reported; ADR, adverse drug reaction; PT, preferred term; IR, incidence rate of mean adverse events per 100 patients per year; N: number of patients. 
Kratice: CTCAE, zajednički terminološki kriteriji za nuspojave; n.z., nije zabilježeno; IR (engl, incidence rate), stopa incidencije srednje vrijednosti broja štetnih događaja na 100 bolesnika po godini; N, broj bolesnika.
What you need to know before you use Besremi 3. 
Što morate znati prije nego počnete primjenjivati Besremi
Besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. 
Besremi je indiciran kao monoterapija u odraslih za liječenje policitemije vere bez simptomatske splenomegalije.
Interferon alfa belongs to the class of type I interferons which exhibit their cellular effects by binding to a transmembrane receptor termed interferon alfa receptor (IFNAR). 
Interferon alfa pripada interferonima skupine tip I koji iskazuju svoje stanične učinke vezivanjem na transmembranski receptor koji sadrži receptor za interferon alfa (IFNAR).
Adverse reactions are listed by system organ class and frequency (very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) or not known (cannot be estimated from available data). 
<1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000) ili nepoznato (ne može se procijeniti iz dostupnih podataka)).
The dose should be gradually increased by 50 micrograms every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilisation of the haematological parameters is achieved (haematocrit <45%, platelets <400 x 109/L and leukocytes <10 x 109/L). 
Dozu treba postupno povećavati za 50 mikrograma svaka dva tjedna (istodobno, drugu citoreduktivnu terapiju treba postupno smanjivati prema potrebi) dok se ne postigne stabilizacija hematoloških parametara (hematokrit <45%, trombociti <400 x 109/l i leukociti <10 x 109/l).
Other CNS effects, 
Učinci na SŽS,
Women of childbearing potential/Contraception in females Women of childbearing potential have to use effective contraception during the treatment with ropeginterferon alfa-2b, unless otherwise discussed with the physician. 
Žene reproduktivne dobi/kontracepcija u žena Žene reproduktivnog potencijala moraju koristiti učinkovitu kontracepciju tijekom liječenja ropeginterferonom alfa-2b, osim ako se ne dogovore drugačije s liječnikom.
• Hold the pen with the needle pointing upwards. 
• Držite brizgalicu s iglom usmjerenom prema gore.
Thus, other products (e.g. hydroxycarbamide) may be preferred in patients for whom an early reduction in elevated blood counts is necessary to prevent thrombosis and bleeding. 
Stoga, drugi lijekovi (npr. hidroksikarbamid) mogu biti poželjni u bolesnika za koje je potrebna rana redukcija u povišenoj razini krvnih stanica za sprječavanje tromboze i krvarenja.
n.r. 
n.z.
Reuse of the pen: 
Ponovna uporaba brizgalice:
• If you are using your pen for the first time, prepare the pen for injection by turning the dose knob until you see the symbol of a “drop”. 
• Ako svoju brizgalicu upotrebljavate po prvi put, pripremite brizgalicu za injekciju tako što ćete okretati kotačić za odabir doze dok ne ugledate simbol „kapljice“.
Each pre-filled pen contains a cartridge (type 1 colourless glass) with a grey plunger (bromobutyl rubber) and a flanged cap (aluminium) with a stopper (bromobutyl rubber). 
Jedna napunjena brizgalica sadrži uložak (bezbojno staklo tipa 1), sa sivim klipom (od bromobutilne gume) i kapicom s prirubnicama (od aluminija) s čepom (od bromobutilne gume).
Cases of pulmonary arterial hypertension (PAH) have been reported with interferon alfa, notably in patients with risk factors for PAH (such as portal hypertension, HIV infection, cirrhosis). 
Slučajevi plućne arterijske hipertenzije (PAH) uočeni su kod primjene interferona alfa, posebice u bolesnika s čimbenicima rizika za PAH (poput portalne hipertenzije, infekcije virusom HIV-a te ciroze).
If a certain dose cannot be set, an insufficient quantity of medicinal product may be left in the pen and a new pen must be used. 
Ako se određena doza ne može podesiti, možda je u brizgalici preostala nedostatna količina lijeka te se mora upotrijebiti nova brizgalica.
• Check the solution through the inspection windows along the sides of the cartridge holder. 
• Provjerite otopinu kroz prozorčić za provjeru smješten na nosaču uloška.
Mean Cmax was 2.4 ng/mL (with a dose of 5080 micrograms) to 49 ng/mL (with a dose of 450 micrograms) and AUC0-t ranged from 28.5 ng.h/mL (with a dose of 50 - 80 micrograms) to 552.6 ng.h/mL (with a dose of 450 micrograms) in patients after subcutaneous multiple dose administration. 
Srednja vrijednost Cmax iznosila je 2,4 ng/ml (s dozom od 50 - 80 mikrograma) do 49 ng/ml (s dozom od 450 mikrograma) te je AUC0-t bio u rasponu od 28,5 ng.h/ml (s dozom od 50 - 80 mikrograma) do 552,6 ng.h/ml (s dozom od 450 mikrograma) u bolesnika nakon višekratnog supkutanog doziranja.
not known retinal detachment# 
nepoznato ablacija mrežnice#
A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from ropeginterferon alfa-2b therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. 
Potrebno je odlučiti da li prekinuti dojenje ili prekinuti liječenje/suzdržati se od liječenja ropeginterferonom alfa-2b, uzimajući u obzir korist dojenja za dijete i korist liječenja za ženu.
It may only be used if the solution is clear, colourless to pale yellow, with no particles visible. 
Otopina se može koristiti samo ako je bistra, bezbojna do blijedožuta te bez vidljivih čestica.
Besremi is presented as a solution for injection (injection) in a pre-filled pen. 
Besremi je dostupan kao otopina za injekciju (injekcija) u napunjenoj brizgalici.
Read them before you start using Besremi. 
Pročitajte ih prije nego počnete primjenjivati lijek Besremi.
The instructions for use in the package leaflet should be followed. 
Potrebno je pridržavati se uputa za uporabu u uputi o lijeku.
You should see a droplet of liquid appearing at the needle tip. 
Morali biste vidjeti kako se na vrhu igle pojavljuje kapljica tekućine.
The Besremi pre-filled pen comes with two needles. 
Besremi napunjena brizgalica isporučuje se s dvije igle.
The mean dose after 12 months of treatment was 382 (±141) micrograms for ropeginterferon alfa-2b. 
Srednja doza nakon 12 mjeseci liječenja bila je 382 (± 141) mikrograma za ropeginterferon alfa-2b.
It is available in packs containing 1 pre-filled pen and 2 injection needles. 
Dostupan je u pakiranjima koja sadrže 1 napunjenu brizgalicu i 2 igle za injekciju.
• Click the needle onto the pen and make sure that it is firmly attached. 
• Nataknite iglu na brizgalicu i pazite da je dobro pričvršćena.
One patient who experienced serious acute stress disorder (0.6%; incidence rate: 0.2 events/100 patients per year) with moderate intensity recovered completely after the dose of ropeginterferon alfa-2b was reduced. 
Jedan bolesnik u kojeg se javio ozbiljni, akutni stresni poremećaj (0,6%; stopa incidencije: 0,2 događaja/100 bolesnika na godinu) s umjerenim intenzitetom u potpunosti se je oporavio nakon smanjenja doze ropeginterferona alfa-2b.
- if you have a liver or kidney disease. 
- ako imate bolest jetre ili bubrega.
While holding the pre-filled pen with the needle pointing upwards, tap the pre-filled pen gently with the fingers so that any air bubbles rise up towards the needle. 
Dok držite napunjenu brizgalicu s iglom usmjerenom prema gore, lagano lupkajte prstima napunjenu brizgalicu tako da se svi mjehurići zraka podignu prema igli.
There are no or limited amount of data from the use of interferon alfa in pregnant women. 
Nema podataka ili su podaci o primjeni interferona alfa u trudnica ograničeni.
Patients showed a statistically significant difference in the JAK2V617F allele burden (19.7%) and JAK2V617F allele change from baseline (-22.9%). 
Bolesnici su pokazali statistički značajnu razliku u opterećenju alelom JAK2V617F (19,7%) te promjeni alela JAK2V617F u odnosu na početnu vrijednost (-22,9%).
The pen can be adjusted to administer doses in 50 microgram intervals in the range of 50 to 250 micrograms or 50 to 500 micrograms. 
Brizgalica se može prilagoditi za primjenu doza u intervalima od 50 mikrograma, u rasponu od 50 do 250 mikrograma ili 50 do 500 mikrograma.
• Set the dose your doctor told you by turning the dose knob. 
• Namjestite dozu koju Vam je liječnik odredio okretanjem kotačića za odabir doze.
Interferon alfa was shown to be abortifacient in primates and ropeginterferon alfa-2b is expected to have a similar effect. 
Pokazano je da interferon alfa ima abortivan učinak u primata te se očekuje da će i ropeginterferon alfa-2b imati sličan učinak.
No dose adaptions for ropeginterferon alfa-2b should be necessary when concomitantly administered with medicinal products metabolised via CYP2C9/19, CYP3A4 or by N-acetyltransferase. 
Neće biti potrebna prilagodba doze ropeginterferona alfa-2b kod istodobne primjene s lijekovima koji se metaboliziraju putem CYP2C9/19, CYP3A4 ili N-acetiltransferazom.
Ropeginterferon alfa-2b treatment was continued and the patients received appropriate medicinal products to treat these events. 
Terapija ropeginterferonom alfa-2b se nastavila, a bolesnici su primili odgovarajuće lijekove za liječenje tih događaja.
Treatment with ropeginterferon alfa-2b should be discontinued when, despite dose reduction, the increase in liver enzyme levels is progressive and clinically significant. 
Liječenje ropeginterferonom alfa-2b treba prekinuti kada je unatoč smanjenju doze, porast razine jetrenih enzima progresivan te klinički značajan.
Over a dose range of 24 to 270 micrograms, ropeginterferon alfa-2b Cmax increased proportionally with dose in a pharmacokinetic study with healthy subjects. 
Za raspon doza od 24 do 270 mikrograma, Cmax ropeginterferona alfa-2b povećavao se proporcionalno s dozom u farmakokinetičkom ispitivanju u zdravih ispitanika.
Likewise, caution is recommended with CYP2D6 substrates (e.g. vortioxetine, risperidone) combined with ropeginterferon alfa-2b. 
Slično tome, preporučuje se oprez sa supstratima CYP2D6 (npr. vortioksetinom, risperidonom) u kombinaciji s ropeginterferonom alfa-2b.
Caution must be exercised when administering ropeginterferon alfa-2b in combination with other potentially myelosuppressive/chemotherapeutic agents. 
Potreban je oprez kada se ropeginterferon alfa-2b primjenjuje u kombinaciji s drugim potencijalno mijelosupresivnim/kemoterapijskim agensima.
If you need a dose of more than 250 micrograms, you require two Besremi 250 microgram pre-filled pens. 
Ako Vam je potrebna doza viša od 250 mikrograma, trebat će Vam dvije napunjene brizgalice lijeka Besremi 250 mikrograma.